Product image of Mayzent (Siponimod) supplied by GNH India

Mayzent

Active Ingredient:
Siponimod
Origin:
EU

Mayzent (Siponimod)

Siponimod, the active ingredient in Mayzent, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as a 2 mg oral tablet for oral use. It is indicated for relapsing forms of multiple sclerosis, including secondary progressive disease with active inflammation, and works by modulating immune cell trafficking.

GNH India supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this disease‑modifying therapy.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mayzent (siponimod) is used within the multiple sclerosis disease family to modify disease activity and reduce relapses.

  • Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and slows disability progression.
  • Secondary progressive multiple sclerosis with active disease: decreases inflammatory activity and delays further disability accumulation.

How It Works

  • Siponimod selectively modulates sphingosine‑1‑phosphate receptors S1P1 and S1P5 on lymphocytes, causing their sequestration within lymph nodes. This reduces the number of circulating lymphocytes that can enter the central nervous system, thereby diminishing neuroinflammatory processes that drive multiple sclerosis activity.

Side Effects

Siponimod may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypertension: increased blood pressure readings.
  • Elevated liver enzymes: transient ALT/AST elevations.
  • Lymphopenia: reduced peripheral lymphocyte count.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Diarrhea: mild gastrointestinal upset.

Serious or Rare Side Effects

  • Severe infections: opportunistic or serious bacterial infections.
  • Macular edema: visual disturbances requiring ophthalmologic assessment.
  • Cardiac conduction abnormalities: bradyarrhythmias or AV block.
  • Severe liver injury: hepatitis or hepatic failure.

Precautions & Warnings

Before initiating Mayzent, several safety considerations should be addressed.

  • Baseline assessment: obtain complete blood count and liver function tests prior to therapy.
  • Infection risk: monitor for signs of infection and defer treatment during active infections.
  • Vaccination: avoid live vaccines while receiving siponimod.
  • Pregnancy: contraindicated in pregnancy; use effective contraception.
  • Drug interactions: review concomitant medications, especially CYP2C9 substrates and inhibitors.
  • Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Avoid Interactions

Siponimod can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • CYP2C9 inhibitors (e.g., fluconazole, amiodarone): may increase siponimod exposure.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower siponimod levels and reduce effectiveness.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may exacerbate bradycardia during treatment initiation.
  • Live vaccines: timing adjustments needed to prevent reduced vaccine efficacy.
  • Antiplatelet or anticoagulant therapy: monitor for increased bleeding risk.

Frequently Asked Questions

Mayzent is prescribed for relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis with active disease. It helps reduce the frequency of relapses and slows the accumulation of disability by targeting immune mechanisms that drive neuroinflammation.

Siponimod selectively binds to sphingosine‑1‑phosphate receptors S1P1 and S1P5 on lymphocytes. This binding traps lymphocytes in lymph nodes, lowering their presence in the bloodstream and central nervous system, which in turn reduces inflammatory attacks on nerve tissue characteristic of multiple sclerosis.

The dose of Mayzent is determined by the prescribing healthcare professional based on the patient’s clinical profile, laboratory results, and treatment guidelines. The prescriber will initiate therapy at the recommended starting dose and may adjust it according to safety and efficacy monitoring.

Siponimod’s safety in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women, and effective contraception is advised during treatment and for a defined period after discontinuation. Breastfeeding considerations should be discussed with a healthcare provider.

To order Mayzent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mayzent (siponimod) and other S1P modulators such as fingolimod share a common mechanism of sequestering lymphocytes, but siponimod is more selective for S1P1 and S1P5 receptors, which may influence efficacy and safety profiles. Clinical trials suggest comparable efficacy in reducing relapse rates, while side‑effect spectra differ slightly, making individual patient factors important in selection.

Mayzent tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture. Keep the product out of direct sunlight and away from excessive heat. Do not store in a refrigerator or freezer.

Mayzent is taken orally as a tablet, usually once daily, with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole and follow any specific instructions regarding dose titration provided by their healthcare professional.

Serious risks include severe infections, macular edema affecting vision, significant cardiac conduction abnormalities such as bradyarrhythmias, and severe liver injury. Patients should promptly report symptoms like fever, visual changes, chest discomfort, or jaundice to their healthcare provider.

Mayzent is contraindicated in individuals with known hypersensitivity to siponimod, those with active severe infections, patients with certain cardiac conditions that predispose to conduction problems, and pregnant women. A thorough medical assessment is required before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Siponimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT